The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function

Hypertension

Volumn , Issue , 2005, Pages 203-218

  Carretero, Oscar A ^a   Yang, Xiao Ping ^b   Rhaleb, Nour Eddine ^c  

^a HENRY FORD HEALTH SCIENCES CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884876350     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50110-1     Document Type: Chapter

References (220)

1. Carretero OA, Scicli AG Kinins paracrine hormone. Kidney Int 1988, 34(Suppl 26):S-52-S-59.
2. Parratt JR, Vegh A, Papp JG Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning: A brief review of the evidence. Can J Physiol Pharmacol 1995, 73:837-842.
3. Yang X-P, Liu Y-H, Scicli GM, et al. Role of kinins in the cardioprotective effect of preconditioning. Study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 1997, 30:735-740.
4. Liu Y-H, Yang X-P, Shesely EG, et al. Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol 2004, 43:1473-1480.
5. Yang X-P, Liu Y-H, Mehta D, et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 2001, 88:1072-1079.
6. Scicli AG, Mindroiu T, Scicli G, et al. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 1982, 100:81-93.
7. Colman RW Patho-physiology of kallikrein system. Ann Clin Lab Sci 1980, 10:220-226.
8. Kaplan AP, Silverberg M The coagulation-kinin pathway of human plasma. Blood 1987, 70:1-15.
9. Sundsmo JS, Fair DS Relationships among the complement, kinin, coagulation and fibrinolytic systems in the inflammatory reaction. Clin Physiol Biochem 1983, 1:225-284.
10. Clements JA The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocr Rev 1989, 10:393-419.
11. Boucher R, Demassieux S, Garcia R, et al. Tonin, angiotensin II system. Circ Res 1977, 41:26-29.
12. Lilja H A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985, 76:1899-1903.
13. Yamaguchi T, Carretero OA, Scicli AG A novel serine protease with vasoconstrictor activity coded by the kallikrein gene S3. J Biol Chem 1991, 266:5011-5017.
14. Yamaguchi T, Carretero OA, Scicli AG A potent vasoconstrictor in the rat submandibular gland. Hypertension 1991, 17:101-106.
15. Carretero OA, Carbini LA, Scicli AG The molecular biology of the kallikrein-kinin system: I. General description, nomenclature and the mouse gene family. J Hypertens 1993, 11:693-697.
16. Scicli AG, Carbini LA, Carretero OA The molecular biology of the kallikrein-kinin system: II. The rat gene family. J Hypertens 1993, 11:775-780.
17. Carbini LA, Scicli AG, Carretero OA The molecular biology of the kallikrein-kinin system: III. The human kallikrein gene family and kallikrein substrate. J Hypertens 1993, 11:893-898.
18. Saed GM, Carretero OA, MacDonald RJ, et al. Kallikrein messenger RNA in rat arteries and veins. Circ Res 1990, 67:510-516.
19. Nolly H, Saed G, Carretero OA, et al. Adrenal kallikrein. Hypertension 1993, 21:911-915.
20. Nolly H, Scicli AG, Scicli G, et al. Characterization of a kinino-genase from rat vascular tissue resembling tissue kallikrein. Circ Res 1985, 56:816-821.
21. Nolly H, Carbini LA, Scicli G, et al. A local kallikrein-kinin system is present in rat hearts. Hypertension 1994, 23:919-923.
22. Chao J, Chao L, Swain CC, et al. Tissue kallikrein in rat brain and pituitary: Regional distribution and estrogen induction in the anterior pituitary. Endocrinology 1987, 120:475-482.
23. Clements JA, Matheson BA, MacDonald RJ, et al. The expression of the kallikrein gene family in the rat pituitary: Oestrogen effects and the expression of an additional family member in the neurointermediate lobe. J Neuroendocrinol 1989, 1:199-203.
24. Powers CA, Nasjletti A A major sex difference in kallikrein-like activity in the rat anterior pituitary. Endocrinology 1984, 114:1841-1844.
25. Frey EK, Kraut H, Werle E Kallikrein padutin [English transl. (1977) ed by R Vogel] 1950, Ferdinand Enke Verlag, Stuttgart.
26. Zimmermann A, Geiger R, Kortmann H Similarity between a kininogenase (kallikrein) from human large intestine and human urinary kallikrein. Hoppe-Seylers Z Physiol Chem 1979, 360:1767-1773.
27. Schachter M, Longridge DJ, Wheeler GD, et al. Immunocytochemical and enzyme histochemical localization of kallikrein-like enzymes in colon, intestine, and stomach of rat and cat. J Histochem Cytochem 1986, 34:927-934.
28. Hilton SM The physiological role of glandular kallikreins. Handbook of Experimental Pharmacology, Vol 25: Bradykinin, Kallidin and Kallikrein. 2nd ed 1970, 389-399. Springer-Verlag, New York. E.G. Erdös (Ed.).
29. Chao J, Chao L, Margolius HS Isolation of tissue kallikrein in rat spleen by monoclonal antibody-affinity chromatography. Biochim Biophys Acta 1984, 801:244-249.
30. Scicli G, Nolly H, Carretero OA, et al. Glandular kallikrein-like enzyme in adrenal glands. Adv Exp Med Biol 1989, 247B:217-222.
31. Rabito SF, Scicli AG, Carretero OA Immunoreactive glandular kallikrein in plasma. Enzymatic Release of Vasoactive Peptides 1980, 247-256. Raven Press, New York. F. Gross, G. Vogel (Eds.).
32. Rabito SF, Scicli AG, Kher V, et al. Immunoreactive glandular kallikrein in rat plasma: A radioimmunoassay for its determination. Am J Physiol 1982, 242:H602-H610.
33. Geiger R, Clausnitzer B, Fink E, et al. Isolation of an enzymati-cally active glandular kallikrein from human plasma by immunoaffinity chromatography. Hoppe Seylers Z Physiol Chem 1980, 361:1795-1803.
34. Lawton WJ, Proud D, Frech ME, et al. Characterization and origin of immunoreactive glandular kallikrein in rat plasma. Biochem Pharmacol 1981, 30:1731-1737.
35. Scicli AG, θrstavik TB, Rabito SF, et al. Blood kinins after sympathetic nerve stimulation of the rat submandibular gland. Hypertension 1983, 5(Suppl I):I-101-I-106.
36. Pisano JJ, Corthorn J, Yates K, et al. The kallikrein-kinin system in the kidney. Contrib Nephrol 1978, 12:116-125.
37. Omata K, Carretero OA, Itoh S, et al. Active and inactive kallikrein in rabbit connecting tubules and urine during low and normal sodium intake. Kidney Int 1983, 24:714-718.
38. Noda Y, Yamada K, Igic R, et al. Regulation of rat urinary and renal kallikrein and prekallikrein by corticosteroids. Proc Natl Acad Sci USA 1983, 80:3059-3063.
39. Alhenc-Gelas F, Marchetti J, Allegrini J, et al. Measurement of urinary kallikrein activity: Species differences in kinin production. Biochim Biophys Acta 1981, 677:477-488.
40. Mindroiu T, Scicli G, Perini F, et al. Identification of a new kinin in human urine. J Biol Chem 1986, 261:7407-7411.
41. Jacobsen S Substrates for plasma kinin-forming enzymes in human, dog and rabbit plasmas. Br J Pharmacol 1966, 26:403-411.
42. Jacobsen S Separation of two different substrates for plasma kinin-forming enzymes. Nature 1966, 210:98-99.
43. Müller-Esterl W, Fritz H, Machleidt W, et al. Human plasma kininogens are identical with α-cysteine proteinase inhibitors: Evidence from immunological, enzymological and sequence data. FEBS Lett 1985, 182:310-314.
44. 2-thiol proteinase inhibitor and its identity with low molecular weight kininogen. Biochemistry 1984, 23:5691-5697.
45. Sueyoshi T, Enjyoji K, Shimada T, et al. A new function of kininogens as thiol-proteinase inhibitors: Inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens. FEBS Lett 1985, 182:193-195.
46. Barlas A, Okamoto H, Greenbaum LM T-kininogen: The major plasma kininogen in rat adjuvant arthritis. Biochem Biophys Res Commun 1985, 129:280-286.
47. Furuto-Kato S, Matsumoto A, Kitamura N, et al. Primary structures of the mRNAs encoding the rat precursors for bradykinin and T-kinin: Structural relationship of kininogens with major acute phase protein and a 1-cysteine proteinase inhibitor. J Biol Chem 1985, 260:12054-12059.
48. Okamoto H, Greenbaum LM Kininogen substrates for trypsin and cathepsin D in human, rabbit and rat plasmas. Life Sci 1983, 32:2007-2013.
49. Okamoto H, Greenbaum LM Pharmacological properties of T-kinin (isoleucyl-seryl-bradykinin) from rat plasma. Biochem Pharmacol 1983, 32:2637-2638.
50. Kaplan AP, Silverberg M, Ghebrehiwet B, et al. The kallikrein-kinin system in inflammation. Adv Exp Med Biol 1989, 247:125-136.
51. Erdös EG Kininases. Handbook of Experimental Pharmacology, Vol XXV, Suppl: Bradykinin, Kallidin and Kallikrein 1979, 427-487. Springer-Verlag, Berlin. E.G. Erdös (Ed.).
52. Erdös EG Angiotensin I converting enzyme. Circ Res 1975, 36:247-255.
53. Skidgel RA, Schulz WW, Tam L-T, et al. Human renal angiotensin I converting enzyme and neutral endopeptidase. Kidney Int 1987, 31(Suppl 20):S-45-S-48.
54. Vijayaraghavan J, Scicli AG, Carretero OA, et al. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 1990, 265:14150-14155.
55. Ura N, Carretero OA, Erdös EG Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987, 32:507-513.
56. Ishida H, Scicli AG, Carretero OA Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension 1989, 14:322-327.
57. Campbell DJ, Kladis A, Duncan A-M Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 1993, 21:155-165.
58. Cherry PD, Furchgott RF, Zawadzki JV, et al. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 1982, 79:2106-2110.
59. Vane JR, Änggård EE, Botting RM Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27-36.
60. Vanhoutte PM Endothelium and control of vascular function: State of the art lecture. Hypertension 1989, 13:658-667.
61. Tiffany CW, Burch RM Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett 1989, 247:189-192.
62. Smith D, Gilbert M, Owen WG Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985, 66:835-839.
63. Regoli D Pharmacology of bradykinin and related kinins. Adv Exp Med Biol 1983, 156:569-584.
64. Regoli D, Rhaleb NE, Drapeau G, et al. Basic pharmacology of kinins: pharmacologic receptors and other mechanisms. Adv Exp Med Biol 1989, 247:399-407.
65. 2 bradykinin receptor. Proc Natl Acad Sci USA 1991, 88:7724-7728.
66. 2 receptor characterization. Trends Pharmacol Sci 1990, 11:156-161.
67. Burch RM, Farmer SG, Steranka LR Bradykinin receptor antagonists. Med Res Rev 1990, 10:237-269.
68. Regoli D, Rhaleb N-E, Drapeau G, et al. Kinin receptor subtypes. J Cardiovasc Pharmacol 1990, 15(Suppl 6):S30-S38.
69. Saha JK, Sengupta JN, Goyal RK Effect of bradykinin on opossum esophageal longitudinal smooth muscle: evidence for novel bradykinin receptors. J Pharmacol Exp Ther 1990, 252:1012-1020.
70. Stewart JM, Vavrek RJ Bradykinin competitive antagonists for classical kinin systems. Kinins IV, Part A 1986, 537-542. Plenum Press, New York. L.M. Greenbaum, H.S. Margolius (Eds.).
71. Regoli D, Barabe J Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32:1-46.
72. Marceau F, Hess JF, Bachvarov DR The B1 receptors for kinins. Pharmacol Rev 1998, 50:357-386.
73. Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: In vivo studies. Br J Pharmacol 1991, 102:774-777.
74. Stewart JM, Gera L, York EJ, et al. Metabolism-resistant bradykinin antagonists: Development and applications. Biol Chem 2001, 382:37-41.
75. Burgess GM, Perkins MN, Rang HP, et al. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 2000, 129:77-86.
76. Whalley ET, Hanson WL, Stewart JM, et al. Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. Can J Physiol Pharmacol 1997, 75:629-632.
77. Stewart JM Bradykinin antagonists as anti-cancer agents. Curr Pharm Des 2003, 9:2036-2042.
78. Bock MG, Longmore J Bradykinin antagonists: New opportunities. Curr Opin Chem Biol 2000, 4:401-406.
79. 2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 2000, 58:828-836.
80. Marcic BM, Erdös EG Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther 2000, 294:605-612.
81. 1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000, 407:94-98.
82. 2 receptor with endothelial nitric-oxide synthase. J Biol Chem 1998, 273:24025-24029.
83. Oza NB, Schwartz JH, Goud HD, et al. Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykin-inase activity. J Clin Invest 1990, 85:597-600.
84. Bergaya S, Meneton P, Bloch-Faure M, et al. Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 2001, 88:593-599.
85. Meneton P, Bloch-Faure M, Hagege AA, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 2001, 98:2634-2639.
86. Mombouli J-V, Illiano S, Nagao T, et al. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyper-polarizing factors. Circ Res 1992, 71:137-144.
87. Clozel M Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension 1991, 18(Suppl II):II-37-II-42.
88. Powell JS, Müller RKM, Rouge M, et al. The proliferative response to vascular injury is suppressed by angiotensin-con-verting enzyme inhibition. J Cardiovasc Pharmacol 1990, 16(Suppl 4):S42-S49.
89. Osterrieder W, Müller RKM, Powell JS, et al. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension 1991, 18(Suppl II):II-60-II-64.
90. Farhy R, Ho K-L, Carretero OA, et al. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992, 182:283-288.
91. Farhy RD, Carretero OA, Ho K-L, et al. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993, 72:1202-1210.
92. Berg T, Carretero OA, Scicli AG, et al. Role of kinin in regulation of rat submandibular gland blood flow. Hypertension 1989, 14:73-80.
93. Seino M, Carretero OA, Albertini R, et al. Kinins in regulation of uteroplacental blood flow in the pregnant rabbit. Am J Physiol 1982, 242:H142-H147.
94. Roman RJ, Kaldunski ML, Scicli AG, et al. Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol 1988, 255:F690-F698.
95. Seino M, Abe K, Nushiro N, et al. Effects of a competitive antagonist of bradykinin on blood pressure and renal blood flow in anesthetized rats. J Hypertens 1988, 6:867-871.
96. θrstavik TB, Carretero OA, Johansen L, et al. Role of kallikrein in the hypotensive effect of captopril after sympathetic stimulation of the rat submandibular gland. Circ Res 1982, 51:385-390.
97. Beierwaltes WH, Carretero OA, Scicli AG Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol 1988, 255:F408-F414.
98. Ren Y, Garvin J, Carretero OA Mechanism involved in bradykinin-induced efferent arteriole dilation. Kidney Int 2002, 62:544-549.
99. + exchangers on the macula densa cells augments tubu-loglomerular feedback. Hypertension 2003, 41:688-691.
100. Zimmerman BG, Raich PC, Vavrek RJ, et al. Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog. Circ Res 1990, 66:234-240.
101. Nakagawa M, Nasjletti A Renal function as affected by inhibitors of kininase II and of neutral endopeptidase 24.11 in rats with and without desoxycorticosterone pretreatment. Adv Exp Med Biol 1989, 247:495-499.
102. Omata K, Carretero OA, Scicli AG, et al. Localization of active and inactive kallikrein (kininogenase activity) in the microdis-sected rabbit nephron. Kidney Int 1982, 22:602-607.
103. Scicli AG, Carretero OA, Hampton A, et al. Site of kininogenase secretion in the dog nephron. Am J Physiol 1976, 230:533-536.
104. Scicli AG, Gandolfi R, Carretero OA Site of formation of kinins in the dog nephron. Am J Physiol 1978, 234:F36-F40.
105. Figueroa CD, MacIver AG, Mackenzie JC, et al. Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 1988, 89:437-442.
106. 3H]bradykinin in isolated nephron segments of the rabbit. Am J Physiol 1984, 246:F732-F737.
107. Vio CP, Churchill L, Rabito SF, et al. Renal kallikrein in venous effluent of filtering and non-filtering isolated kidneys. Adv Exp Med Biol 1983, 156B:897-905.
108. Siragy HM, Jaffa AA, Margolius HS Stimulation of renal interstitial bradykinin by sodium depletion. Am J Hypertens 1993, 6:863-866.
109. 22Na in the rat nephron. J Pharmacol Exp Ther 1980, 214:119-123.
110. Kauker ML Kallidin effect on renal tubular function in meclofenamate- and vehicle-pretreated rats. Proc Soc Exp Biol Med 1990, 193:60-64.
111. Kauker ML, Gisi PJ, Zawada ET Renal kinins and sodium transport: Influence of a bradykinin receptor antagonist (BKRA) [abstract]. FASEB J 1990, 4:A990.
112. Sybertz EJ, Chiu PJS, Vemulapalli S, et al. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826: An orally active neutral metalloendopeptidase inhibitor. Hypertension 1990, 15:152-161.
113. Pollock DM, Butterfield MI, Ader JL, et al. Dissociation of urinary kallikrein activity and salt and water excretion in the rat. Am J Physiol 1986, 250:F1082-F1089.
114. Nasjletti A, McGiff JC, Colina-Chourio J Interrelations of the renal kallikrein-kinin system and renal prostaglandins in the conscious rat. Influence of mineralocorticoids. Circ Res 1978, 43:799-807.
115. Marin Grez M The influence of antibodies against bradykinin on isotonic saline diuresis in the rat. Evidence for kinin involvement in renal function. Pflugers Arch 1974, 350:231-239.
116. Düsing R, Struck A, Göbel BO, et al. Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 1990, 38:315-319.
117. 2, water, and sodium excretion. Hypertension 1995, 25:1008-1013.
118. Stoos BA, Carretero OA, Farhy RD, et al. Endothelium-derived relaxing factor inhibits transport and increases cGMP content in cultured mouse cortical collecting duct cells. J Clin Invest 1992, 89:761-765.
119. Lahera V, Salom MG, Fiksen-Olsen MJ, et al. Mediatory role of endothelium-derived nitric oxide in renal vasodilatory and excretory effects of bradykinin. Am J Hypertens 1991, 4:260-262.
120. Sinaiko AR, Glasser RJ, Gillum RF, et al. Urinary kallikrein excretion in grade school children with high and low blood pressure. J Pediatr 1982, 100:938-940.
121. Uchiyama M, Otsuka T, Sakai K Urinary kallikrein excretion in children of parents with essential hypertension. Arch Dis Child 1985, 60:974-975.
122. Wollheim E, Peterknecht S, Dees C, et al. Defect in the excretion of a vasoactive polypeptide fraction A possible genetic marker of primary hypertension. Hypertension 1981, 3:574-579.
123. Zinner SH, Margolius HS, Rosner B, et al. Familial aggregation of urinary kallikrein concentration in childhood: Relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 1976, 104:124-132.
124. Pravenec M, Kren V, Kunes J, et al. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 1991, 17:242-246.
125. Carretero OA, Amin VM, Ocholik T, et al. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt. A new radioimmunoassay for its direct determination. Circ Res 1978, 42:727-731.
126. Carretero OA, Polomski C, Hampton A, et al. Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin Exp Pharmacol Physiol 1976, 3(Suppl):55-59.
127. Carretero OA, Scicli AG, Piwonska A, et al. Urinary kallikrein in rats bred for susceptibility and resistance to the hypertensive effect of salt and in New Zealand genetically hypertensive rats. Mayo Clin Proc 1977, 52:465-467.
128. Keiser HR, Geller RG, Margolius HS, et al. Urinary kallikrein in hypertensive animal models. Fed Proc 1976, 35:199-202.
129. Carretero OA, Scicli AG The renal kallikrein-kinin system in human and in experimental hypertension. Klin Wochenschr 1978, 56(Suppl I):113-125.
130. Holland OB, Chud JM, Braunstein H Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest 1980, 65:347-356.
131. Margolius HS, Horwitz D, Pisano JJ, et al. Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 1974, 35:820-825.
132. Seino M, Abe K, Otsuka Y, et al. Urinary kallikrein excretion and sodium metabolism in hypertensive patients. Tohoku J Exp Med 1975, 116:359-367.
133. 2 in genetically hypertensive mice. Proc Soc Exp Biol Med 1980, 163:193-199.
134. Bönner G, Preis S, Schunk U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990, 15(Suppl 6):S46-S56.
135. Salgado MCO, Rabito SF, Carretero OA Blood kinin in one-kidney, one clip hypertensive rats. Hypertension 1986, 8(Suppl I):I-110-I-113.
136. Benetos A, Gavras I, Gavras H Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension 1986, 8:1089-1092.
137. Beierwaltes WH, Carretero OA, Scicli AG, et al. Competitive analog antagonists of bradykinin in the canine hindlimb. Proc Soc Exp Biol Med 1987, 186:79-83.
138. Carbonell LF, Carretero OA, Madeddu P, et al. Effects of a kinin antagonist on mean blood pressure. Hypertension 1988, 11(Suppl I):I-84-I-88.
139. Rhaleb N-E, Yang X-P, Nanba M, et al. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension 2001, 37:121-128.
140. 2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension 1993, 21:980-984.
141. Majima M, Katori M, Hanazuka M, et al. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 1991, 17:806-813.
142. Majima M, Yoshida O, Mihara H, et al. High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension 1993, 22:705-714.
143. Majima M, Mizogami S, Kuribayashi Y, et al. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 1994, 24:111-119.
144. 2-receptors enhances the slow vasopressor response to angiotensin II. Hypertension 1994, 23:646-652.
145. 2 receptor knockout mice. Biochem Biophys Res Commun 1996, 224:625-630.
146. 2 receptor null mice. Hypertension 1999, 34:176-180.
147. 2 receptors play a role?. Hypertension 1999, 33:329-334.
148. 2 receptor knockout mice. Circulation 1999, 100:2359-2365.
149. 2-KO mice [abstract]. FASEB J 2001, 15:A101.
150. 2 receptor. Hypertension 2001, 37:1473-1479.
151. 2 receptor- and tissue kallikrein-deficient mice. Hypertension 2002, 40:90-95.
152. Carretero OA, Kuk P, Piwonska SS, et al. Role of the renin-angiotensin system in the pathogenesis of severe hypertension in rats. Circ Res 1971, 29:654-663.
153. Marks ES, Bing RF, Thurston H, et al. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): The role of factors other than renin-angiotensin blockade in the rat. Clin Sci 1980, 58:1-6.
154. Cachofeiro V, Sakakibara T, Nasjletti A Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992, 19:138-145.
155. Carbonell LF, Carretero OA, Stewart JM, et al. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988, 11:239-243.
156. Scicli AG, Carretero OA The kallikrein-kinin system as a regulator of cardiovascular and renal function. Hypertension: Physiology, Diagnosis, and Management. 2nd ed 1995, 983-999. Raven Press, New York. J.H. Laragh, B.M. Brenner (Eds.).
157. Campbell DJ The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 2001, 28:1060-1065.
158. Clappison BH, Anderson WP, Johnston CI Role of the kallikrein-kinin system in the renal effects of angiotensin-con-verting enzyme inhibition in anaesthetized dogs. Clin Exp Pharmacol Physiol 1981, 8:509-513.
159. McCaa RE Studies in vivo with angiotensin I converting enzyme (kininase II) inhibitors. Fed Proc 1979, 38:2783-2787.
160. Nasjletti A, Colina-Chourio J, McGiff JC Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 1975, 37:59-65.
161. Vinci JM, Horwitz D, Zusman RM, et al. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E and angiotensin II in hypertensive man. Hypertension 1979, 1:416-426.
162. Carretero OA, Miyazaki S, Scicli AG Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981, 3:18-22.
163. Carretero OA, θrstavik TB, Rabito SF, et al. Interference of converting enzyme inhibitors with the kallikrein-kinin system. Clin Exp Hypertens [A] 1983, 5:1277-1285.
164. Carretero OA, Scicli AG, Maitra SR Role of kinins in the pharmacological effects of converting enzyme inhibitors. Angiotensin Converting Enzyme Inhibitors: Mechanisms of Action and Clinical Implications 1981, 105-121. Urban & Schwarzenberg, Baltimore. Z.P. Horovitz (Ed.).
165. Benetos A, Gavras H, Stewart JM, et al. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 1986, 8:971-974.
166. Danckwardt L, Shimizu I, Bönner G, et al. Converting enzyme inhibition in kinin-deficient Brown Norway rats. Hypertension 1990, 16:429-435.
167. Pontieri V, Lopes OU, Ferreira SH Hypotensive effect of captopril. Role of bradykinin and prostaglandinlike substances. Hypertension 1990, 15(Suppl I):I-55-I-58.
168. Murphey LJ, Vaughan DE, Gainer JV, et al. Angiotensin-con-verting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000, 102:829-832.
169. Overlack A, Stumpe KO, Heck I, et al. Identification of angiotensin II- and kinin-dependent mechanisms in essential hypertension. Hypertension: Mechanisms and Management 1980, 183-191. Springer-Verlag, Berlin. T. Philipp, A. Distler (Eds.).
170. Gainer JV Morrow JD, King DJ, et al. Effect of bradykinin receptor blockade on response to angiotensin converting enzyme inhibition in salt-deplete normotensive subjects. N Engl J Med (submitted).
171. Bao G, Gohlke P, Qadri F, et al. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992, 20:74-79.
172. Nakagawa M, Nasjletti A Plasma kinin concentration in deoxycorticosterone-salt hypertension. Hypertension 1988, 11:411-415.
173. Carretero OA High-mineralocorticoid conditions: Kinins (paracrine hormones) in the regulation of renal function and blood pressure. Progress in Endocrinology: The Proceedings of the Ninth International Congress of Endocrinology, Nice, 1992 1993, 536-540. Parthenon Publications Group, Carnforth, Lancastershire, UK. R. Mornex, C. Jaffiol, J. Leclère (Eds.).
174. Gohlke P, Linz W, Schölkens BA, et al. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 1994, 23:411-418.
175. Rhaleb N-E, Yang X-P, Scicli AG, et al. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994, 23:865-868.
176. Schölkens BA, Linz W, Martorana PA Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: Beyond blood pressure reduction. J Cardiovasc Pharmacol 1991, 18(Suppl 2):S26-S30.
177. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992, 105:771-772.
178. Fernandez LA, Twickler J, Mead A Neovascularization produced by angiotensin II. J Lab Clin Med 1985, 105:141-145.
179. Unger T, Mattfeldt T, Lamberty V, et al. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992, 20:478-482.
180. Hashimoto K, Hamamoto H, Honda Y, et al. Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am Heart J 1978, 95:619-626.
181. Noda K, Sasaguri M, Ideishi M, et al. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993, 27:334-340.
182. Pan H-L, Chen S-R, Scicli GM, et al. Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning. Am J Physiol Heart Circ Physiol 2000, 279:H116-H121.
183. Martorana PA, Kettenbach B, Breipohl G, et al. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990, 182:395-396.
184. Linz W, Wiemer G, Schölkens BA ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 1992, 24:909-919.
185. Linz W, Martorana PA, Schölkens BA Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990, 15(Suppl 6):S99-S109.
186. Shimamoto K, Miura T, Miki T, et al. Activation of kinins on myocardial ischemia. Agents Actions 1992, 38:90-97.
187. Hartman JC, Wall TM, Hullinger TG, et al. Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993, 21:996-1003.
188. Witherow FN, Helmy A, Webb DJ, et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 2001, 104:2177-2181.
189. Liu Y-H, Yang X-P, Mehta D, et al. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol 2000, 278:H507-H514.
190. Liu Y-H, Yang X-P, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997, 99:1926-1935.
191. Liu Y-H, Yang X-P, Sharov VG, et al. Role of kinins, nitric oxide and prostaglandins in the protective effect of ACE inhibitors on ischemia/reperfusion myocardial infarction in rats [abstract]. Hypertension 1994, 24:380.
192. Yang X-P, Liu Y-H, Shesely EG, et al. Endothelial nitric oxide gene knockout mice. Cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 1999, 34:24-30.
193. Linz W, Wiemer G, Schölkens BA Role of kinins in the pathophysiology of myocardial ischemia: In vitro and in vivo studies. Diabetes 1996, 45(Suppl 1):S51-S58.
194. Rubin LE, Levi R Protective role of bradykinin in cardiac anaphylaxis. Coronary- vasodilating and antiarrhythmic activities mediated by
195. Goto M, Liu Y, Yang X-M, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995, 77:611-621.
196. Vegh A, Szekeres L, Parratt JR Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res 1990, 24:1020-1023.
197. Schoelkens BA, Linz W Bradykinin-mediated metabolic effects in isolated perfused rat hearts. Agents Actions 1992, 38(Suppl):36-42.
198. Rett K, Wicklmayr M, Dietze GJ, et al. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996, 45(Suppl 1):S66-S69.
199. Ytrehus K, Liu Y, Downey JM Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994, 266:H1145-H1152.
200. Speechly-Dick ME, Mocanu MM, Yellon DM Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res 1994, 75:586-590.
201. Wolfrum S, Schneider K, Heidbreder M, et al. Remote preconditioning protects the heart by activating myocardial PKCe-isoform. Cardiovasc Res 2002, 55:583-589.
202. Menasché P, Kevelaitis E, Mouas C, et al. Preconditioning with potassium channel openers. A new concept for enhancing car-dioplegic protection?. J Thorac Cardiovasc Surg 1995, 110:1606-1613.
203. Brew EC, Mitchell MB, Rehring TF, et al. Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart. Am J Physiol 1995, 269:H1370-H1378.
204. 2-kinin receptor knockout mice. Hypertension 1999, 34:563-567.
205. Liu Y-H, Xu J, Yang X-P, et al. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 2002, 39:375-381.
206. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992, 327:669-677.
207. Gertz SD, Kurgan A Tissue plasminogen activator and selective coronary vasodilation [letter]. Am J Cardiol 1988, 62:173.
208. Seyedi N, Xu X, Nasjletti A, et al. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995, 26:164-170.
209. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999, 104:925-935.
210. 1 antagonists in mice. Hypertension 2002, 40:244-250.
211. Ferrario CM Angiotensin-(1-7) and antihypertensive mechanisms. J Nephrol 1998, 11:278-283.
212. Freeman EJ, Chisolm GM, Ferrario CM, et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996, 28:104-108.
213. Ferrario CM, Averill DB, Brosnihan KB, et al. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int 2002, 62:1349-1357.
214. Gorelik G, Carbini LA, Scicli AG Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 1998, 286:403-410.
215. Abbas A, Gorelik G, Carbini LA, et al. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension 1997, 30:217-221.
216. Brosnihan KB, Li P, Ferrario CM Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996, 27:523-528.
217. Chappell MC, Gomez MN, Pirro NT, et al. Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension 2000, 35:348-352.
218. Chappell MC, Allred AJ, Ferrario CM Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant 2001, 16(Suppl 1):22-26.
219. 2) angiotensin receptor. Proc Natl Acad Sci USA 1999, 96:6506-6510.
220. Carretero OA Kinins: Local hormones in regulation of blood pressure and renal function. Choices Cardiol 1993, 7(Suppl 1):10-14.